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Introduction
Ataxia telangiectasia (AT) results from bi-allelic constitu-
tional mutations in the Ataxia Telangiectasia Mutated (ATM)
gene on chromosome 11q23. AT is characterized by a 200-
fold increased risk of lymphoid tumors1 and carriers are also
at an increased risk of cancer development albeit at a much
lower level.2 Sporadic ATM mutations have been detected in
tumor cells in patients with various lymphoid malignancies
including B-cell chronic lymphocytic leukemia (CLL).3-5 The
ATM protein signals cellular responses to DNA damage in the
form of DNA double strand breaks (DSBs) and prevents accu-
mulation of potentially tumorigenic cells with unrepaired
DNA DSBs.1
The diagnosis of CLL requires a B-cell clone of more than
5¥109 cells/L of blood with characteristic cell surface markers.
Individuals with a CLL clone of less than 5¥109/L and no addi-
tional pathological features are classified as having the pre-
malignant condition monoclonal B-cell lymphocytosis
(MBL).6,7 CLL shows marked clinical heterogeneity and prog-
nostic markers associated with a poor outcome include dele-
tions of chromosomes 17p and 11q, leading to loss of TP53
and ATM alleles, respectively.8 Mutations in ATM are linked
to poor prognosis and are commonly, but not exclusively,
associated with a chromosome 11q23 deletion. We found
that 36% of CLLs with an 11q deletion carry a mutation in
the remaining ATM allele resulting in bi-allelic ATM defects.3,4
Instances of familial occurrence are recognized in CLL9 and
registry studies confirm that first degree relatives of CLL
patients have a 7-fold increased risk of developing CLL.10
Relatives are also at an increased rate of MBL.11 Within CLL
pedigrees there are no consistent patterns of leukemic devel-
opment suggesting involvement of multiple low risk alleles
rather than a single high-risk locus.9 Recent genome wide
association studies provide evidence for low penetrance risk
alleles that together may increase an individual’s risk of
developing CLL.12,13
ATM mutations occur at different stages of CLL develop-
ment and in occasional cases an ATMmutation is present in a
patient’s germline.3,4,14 In one previous study, ATM mutations
were not found to be responsible for CLL familial clustering;15
however, the role of constitutional pathogenic ATM muta-
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Ataxia telangiectasia patients, with constitutional bi-allelic
ATM mutations, have a marked risk of lymphoid tumors and
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leukemia and are often associated with chromosome 11q
deletions which cause loss of an ATM allele. The role of con-
stitutional ATM mutations in the pathogenesis of chronic
lymphocytic leukemia is unknown. Here we investigated the
frequency of constitutional ATM mutations in either of two
chronic lymphocytic leukemia cohorts, those with and with-
out a chromosome 11q deletion. We found that in compari-
son to controls, constitutional pathogenic ATM mutations
were increased in patients with chromosome 11q deletions (6
of 140 vs. 0 of 281, P=0.001) but not in those without 11q
deletions (2 of 178 vs. 0 of 281, P=0.15). These results suggest
that ATM germline heterozygosity does not play a role in
chronic lymphocytic leukemia initiation but rather influences
rapid disease progression through ATM loss.
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ABSTRACT
tions in the pathogenesis of CLL remains unknown. In this
study, we have addressed the role of ATM carrier status in
two CLL cohorts. We compared the frequency of constitu-
tional ATM mutations in 140 CLL patients with an 11q
deletion, where ATM mutation is a frequent genetic
event,4 and 178 CLL patients with no 11q deletion, where
ATM mutations are rare,3 with 281 healthy controls. 
Design and Methods
CLL and control cohorts
CLL cohorts were taken from patients treated on the UK CLL4
Trial and at Birmingham, Bournemouth and Leicester hospitals.
All were diagnosed according to standard criteria and had had flu-
orescence in situ hybridization (FISH) performed with the ATM
(11q23) probe. Controls included a volunteer research subgroup
(n=71) and anonymous blood donors (n=210). Ethical approval
was obtained from South Birmingham Ethics Committee (ref.
O4/Q2709/25).
Mutational analysis of the ATM gene
Genomic DNA was extracted from mononuclear cells, as previ-
ously described.3,4 Screening for ATM sequence changes was per-
formed using denaturing high-performance liquid chromatogra-
phy (DHPLC).3,4 DHPLC is able to detect mutations present in just
5-10% of the total cell population.16 The PCR products were
sequenced whenever variant chromatogram patterns were detect-
ed.3,4 Sequence changes were compared to published results17,18
and ATM databases (http://chromium.liacs.nl/LOVD2/home.php). To
exclude consideration of rare polymorphisms, sequence changes
were classified as pathogenic mutations only if they were previous-
ly reported as causative mutations in AT patients or were predict-
ed to cause protein truncation. When an ATM mutation was
detected in the leukemic cells from a CLL case, subsequent analy-
sis of constitutional DNA was performed on either buccal cells or
peripheral blood (PB) granulocytes. When PB granulocytes were
used, we adopted a strategy to ensure changes were genuine
germline mutations and not due to contamination with leukemia
cells. Mutations were classified as acquired if the heteroduplex
peak area representing mutation in the CLL DNA was either
absent from the granulocyte DNA or represented less than 40%
of the peak area observed in the corresponding tumor DNA.
Mutations were classified as germline if the peak area in the gran-
ulocyte DNA represented more than 90% of that seen in the CLL
DNA. To validate this approach, we amplified clonal VDJ recom-
binations from representative paired samples (Online
Supplementary Figure S1A and B).
Analysis of immunoglobulin gene usage and class
switch recombination (CSR)
Immunoglobulin heavy chain (IGH) VDJ rearrangements were
amplified using primers corresponding to the consensus sequences
of the framework 1 (FR1) and joining (J6) region. Nucleotide
sequences were analyzed as previously described.19 IGHV genes
were classified as unmutated if there was 98% or more homology
with the parent sequence. Analysis of CSR involved amplification
of the Sm–Sα and Sm–Sγ switch joints, as previously described.20
The amplified sequences were aligned using Basic Local Alignment
Search Tool database (http://www.ncbi.nlm.nih.gov/BLAST/).
Statistical analysis
Fisher’s exact t-test was used for comparisons of param-
eters and the Kaplan-Meier method was used to deter-
mine survival outcomes.
Results and Discussion
ATM sequence changes in CLL patients and controls
We analyzed the ATM coding region in 318 CLL patients
(140 with a chromosome 11q deletion and 178 with no
11q deletion) and 281 controls. Altogether, 85 unique
sequence changes were detected in CLL patients, which
included 19 changes that were also found in control indi-
viduals and 66 changes that were only observed among
CLL patients. Sixty of these CLL-specific changes were
identified in just one CLL patient, and 6 were identified in
more than one CLL case. Thirty-one changes were classi-
fied as pathogenic ATMmutation using our stringent crite-
ria. The remaining changes represented 27 known poly-
Table 1. Pathogenic ATM mutations within the CLL patients.
Sequence change Amino acid Chromosome Previously
change 11q deletion observed 
in AT patients
a) Pathogenic germline ATMmutations
c.1066-6T>G splicing site exon 11 Yes Yes
c.2720_2723delGTGT p.(Cys907fs) Yes Yes
c.3712_3716delTTATT p.(Leu1238fs) Yes Yes
c.5228C>T ** p.(Thr17431Ile) Yes Yes
c.7638_7646del9 p.(Arg2547_Ser2549del) Yes Yes
c.8977C>T p.(Arg2993X) Yes Yes
c.1058_1059delGT p.(Cys353fs) No No
c.8266A>T p.(Lys2756X) No Yes
b) Pathogenic acquired ATMmutations
c.1120C>T p.(Gln374X) Yes Yes
c.1402delAA p.(Lys468fs) Yes Yes
c.2308G>T p.(Glu770X) Yes No
c.3651delG p.(Leu1217fs) Yes No
c.3720_3736del17 p.(Asn1240fs) Yes No
c.4591C>T p.(Gln1531X) Yes No
c.5006-2A>G splicing site exon 36 Yes No
c.6375insT p.(Glu2126fs) Yes Yes
c.6815delA p.(Glu2272fs) Yes No
c.6989_6995del7 p.(Leu2330fs) Yes No
c.7883_7887del5 p.(Ile2628fs) Yes Yes
c.8246_8252del7insT p.(Lys2749_Thr2751delinsIle) Yes No
c.8672-1G>T splicing site exon 62 Yes No
c.9023G>A p.(Arg3008His) Yes Yes
c.2466+2T>G splicing site exon 18 No No
c.4095_4109+4del19 p.(Lys1365fs) No No
c.5228C>T p.(Thr17431Ile) No Yes
c.8834_8867del34 p.(Lys2945fs) No No
c.9022C>T p.(Arg3008Cys) No Yes
c) Pathogenic ATMmutations with unknown germline status
c.478_482delTCTCA p.(Ser160fs) Yes No
c.3883_3885delCTT p.(Lys1295del) Yes No
c.8672G>A p.(Gly2891Asp) Yes Yes
c.9139C>T p.(Arg3047X) Yes Yes
c.2193delC p.(Tyr731fs) No No
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morphisms and 27 missense ‘sequence variants’, where
the pathogenecity of the specific sequence change has not
been proven. In total, 35 unique sequence changes were
detected in controls including the 19 changes that were
common to both CLLs and controls. Twenty-nine changes
were known polymorphic variants, 6 were classified as
sequence variants and no changes fulfilled our criteria for
a pathogenic ATM mutation (Online Supplementary Tables
S1 and S2).
Pathogenic constitutional ATM mutations
The pathogenic ATM mutations occurred in 24 CLLs
with an 11q deletion and 8 CLLs without an 11q deletion
(Table 1). Amongst CLLs with an 11q deletion, 6 muta-
tions were of germline origin, 14 were acquired in
leukemic DNA and 4 remained of unknown origin due to
lack of germline material. Amongst CLLs without a chro-
mosome 11q deletion, 2 mutations were constitutional, 5
were acquired and one of unknown origin. In cases with
a. skowronska et al.
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Table 2. Clinical and biological characteristics of CLL in ATM germline mutation carriers.
Germline Age at Presence Stage at VDJ profile CSR joint TTFT (mths) OS (mths)
ATM mutation diagnosis (years) of 11q deletion diagnosis profile
c.1058_1059delGT 61 No B V1-2/D21-9/J4 NA 0 90
UM
c.2720_2723delGTGT 65 Yes B V1-69/D3/J6  UM NA 0 93+
V3-13/D3/J6  UM
c.3712_3716delTTATT 71 Yes B V3-30/D3/J6 NA 1 43
UM
c.5228C>T 66 Yes A VH3-11/D3/J4 cNHEJ 9.5 78+
UM
c.7638_7646del9 68 Yes C V4-4/D3/J6 NA 0 1
UM
c.8266A>T 52 No B V3-15/D4/J3 NA 1 95+
M
c.8977C>T 51 Yes B V1-18/D3/J4 cNHEJ 0 59.5
M
c.1066-6T>G 60 Yes B V1-69/D3/J6 NA 69 104
UM
UM-VH gene is unmutated, M-VH gene is mutated. NK: not known; CSR: class switch recombination; NA-CSR joint not amplified; cNHEJ-classical non-homologous end joining; TTFT:
time to first treatment in months; OS: overall survival from diagnosis in months; +: indicates censored patient at time of analysis.
Figure 1. Model for CLL development in ATM mutation carriers. The upper panel represents a model for CLL pathogenesis in an ATM germline
mutation carrier. CLL clonal initiation occurs independently of the germline ATM mutation but all cells within the clone will carry the ATM
mutation because this is present in all body cells (a). Subsequent loss of chromosome 11q in any CLL cell (b) will lead to loss of ATM function
resulting in apoptotic resistance and a selective pressure for rapid clonal expansion and disease progression (c). By comparison, the lower
panel represents a model of CLL pathogenesis with wild-type germline ATM. Following clonal initiation (d), subsequent development of an
acquired ATM mutation or chromosome 11q deletion might be expected to initially exert limited selective pressure (e,f).  Only if both defects
are acquired within a cell does loss of ATM function occur and rapid clonal expansion (g,h). Loss of ATM function will occur less frequently
and over a more prolonged time course in this model than in the germline ATM mutation model and here development of alternative genetic
events may influence disease progress rather than ATM/11q defects (not illustrated).
an 11q deletion, 3 germline mutations were predicted to
lead to a truncated protein (c.2720_2723delGTGT,
c.3712_3716delTTATT, c.8977C>T), one to an amino acid
substitution (c.5228C>T [p.T1743I]), one to an in-frame
deletion (c.7638_7646del9 [p.R2547_S2549del]) and one to
altered splicing (skipping of exon 11) (c.1066-6T>G). In
non-11q deleted CLLs, both constitutional mutations
(c.1058_1059delGT, c.8266A>T) were predicted to lead to
premature termination of the protein. Seven out of 8 of
the constitutional mutations have been previously report-
ed in AT families.17,18 Consideration of the two separate
CLL cohorts demonstrated that in comparison to controls,
constitutional pathogenic ATMmutations are significantly
more common in CLL patients who develop a chromo-
some 11q deletion (6 of 140 vs. 0 of 281, P=0.001) but not
in those who do not subsequently acquire this deletion in
their leukemic clone (2 of 178 vs. 0 of 281, P=0.15).
Characteristics of the pathogenic ATM
mutation carriers 
We compared patients’ characteristics between those
with constitutional ATM mutations, acquired ATM muta-
tions, ATM sequence variants (with no additional ATM
mutation) and those with ATM wild-type or known ATM
polymorphisms (Table 2, Online Supplementary Table S3).
Overall there was no difference in stage at diagnosis or VH
mutations status between the 4 categories, but notably
amongst patients with constitutional ATMmutations, 7 of
8 were advanced stage at diagnosis and 6 of 8 had unmu-
tated VH genes. There was a significant difference in over-
all survival between these groups (P=0.005). Patients with
constitutional and acquired ATM pathogenic mutations
and those with ATM sequence variants all had inferior sur-
vival compared to those with wild-type ATM.
The ATM protein ensures fidelity of CSR and prevents
use of non-classical non-homologous end joining (NHEJ).21
We investigated CSR and VDJ profiles in CLL cells of ATM
mutant carriers.22 Both CLLs analyzed were found to have
normal CSR joints. Two patients had a CLL clone carrying
the V1-69/D3/J6 segment pattern22 and the remaining
cases showed a range of V segments (Table 2). 
Acquired defects in ATM are common in CLL and their
impact on cellular phenotype and clinical prognosis has
already been established.3,4 Constitutional ATM mutations
have rarely been identified in CLL patients but their con-
tribution to the pathogenesis of CLL is unknown.18,19 Here
we show that, in comparison to controls, a significantly
increased frequency of constitutional pathogenic ATM
mutant alleles occurs specifically within the subset of CLL
patients who subsequently develop a deletion of chromo-
some 11q in their leukemic cells. 
In this study, we used highly stringent criteria to classify
pathogenic ATM mutations. Classification of missense
changes is difficult and although features such as occur-
rence within functional domains and acquisition within
cancer cells suggest pathogenecity, the only way to prove
functional consequences is by mutation modeling. Given
our focus in this study on constitutional changes, where
classification can be more difficult, we used more strin-
gent criteria than in previous publications. Consequently,
certain changes previously classified as mutations were
here labeled as sequence variants. The poor survival out-
come observed in the ‘sequence variant’ group is interest-
ing and suggests many of these changes may indeed be
exerting functional consequences.
Control and CLL cohorts were not age matched but
there was no reason to indicate imposed bias.  If controls
were younger than patients, then some individuals could
develop CLL in later life. Given an incidence of CLL of 4
per 100,000, this would be a rare event.6 It is possible that
the number of pathogenic germ-line ATM mutations was
higher among CLL patients than we were able to demon-
strate.  In 4 patients with and one without a chromosome
11q deletion, pathogenic ATM mutations were identified
but constitutional material was not available. Thus, the
frequency of ATM mutation carriers in CLL patients could
have been underestimated; but even if all of these 5 cases
carried constitutional ATM mutations it would not alter
the significance of our findings.
The finding of a significantly increased frequency of ATM
carriers only amongst the 11q deleted CLL subgroup sug-
gested that the principal effect of a germline ATMmutation
might be on progression rather than leukemia initiation.
Several lines of evidence support this interpretation. First,
there is no evidence of an increased frequency of CLL
among AT family members.2 Second, chromosome 11q
deletion in leukemic cells is generally considered a late
event in CLL pathogenesis suggesting that complete loss of
ATM function occurs after initial clonal proliferation.23
Finally, here we observed no evidence for the effect of ATM
loss on cellular processes, such as CSR and VDJ segment
usage, that might be associated with CLL initiation.24 Thus,
we propose a model whereby ATM germline mutations do
not contribute to CLL initiation but rather predispose to
rapid disease progression through acquired chromosome
11q deletions, loss of ATM activity and clonal expansion
(Figure1). In keeping with this model, we found that most
ATM mutant carriers were already high stage at diagnosis.
Furthermore, although our entire CLL cohort was biased
for patients with advanced disease, via selection for 11q
deletion and inclusion of CLL4 trial patients, carriers of
ATM mutations still demonstrated short overall survival.
Many cases of CLL are preceded by an asymptomatic
MBL and studies suggest a prevalence of MBL of 3.5% and
a transformation rate to CLL of 1% per annum.7 Given this
prevalence, it is likely that occasional ATMmutation carri-
ers will develop MBL by chance during their lifetime and
in such individuals there will be selective pressure for the
loss of a second ATM allele by 11q deletion leading to an
aggressive leukemia phenotype characterized by impaired
DNA damage induced apoptosis and genomic instability.1,4
This explanation is in keeping with our finding of an
excess of ATM carriers amongst the CLL cohort who had
a chromosome 11q deletion.
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